ImmunoPrecise Antibodies Ltd
#3204 4464 Markham Street
Canada V8Z 7X8
Phone: (800) 620-4187
ImmunoPrecise Antibodies Ltd (“IPA” or “the Company”) is a full-service contract research organization (CRO)† for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets. IPA is transforming the conventional, multivendor, product development model by bringing innovative, high-throughput, data driven discovery services to its partners. IPA has proven its ability to produce well characterized, functional therapeutic lead candidates rapidly and cost-efficiently. In addition to its CRO services, IPA’s wholly-owned subsidiary, Talem Therapeutics LLC (“Talem”), offers research and development (R&D) to support its internally-owned and partnered therapeutic asset development. Talem is working towards building an intellectual property (IP) estate and portfolio of physical assets through internal research and collaborations, and is moving into preclinical analysis and functional studies with roughly half a dozen later-stage preclinical candidates. This portfolio contains novel therapeutic antibodies and vaccines in areas such as infectious disease (i.e. SARS-CoV-2), cardiovascular pathology, neurology, immuno-oncology, inflammation, and rare/specialty diseases. With headquarters in Canada, the Company has offices in the U.S. and Europe. Having gone public in 2016, IPA is dual listed on both the NASDAQ and the TSX Venture Exchange (TSXV) under the symbol “IPA”.
* The Corporate Snapshot was last updated on May 18, 2022.